|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Recombinant tissue plasminogen activator enhances microglial cell recruitment after stroke in mice显示文摘 | Lenglet S Monteeucco F Denes A | 2014 | J Cereb Blood Flow Metab2014，34，5： | 1 |
| 2 | Use of nicotinamide to treat hyperphosphatemia in dialysis patients显示文摘 | Lenglet A Liabeuf S Guffroy P | 2013 | Drugs R D2013，13，3： | 1 |
| 3 | Plasma beta-2 microglob- ulin is associated with cardiovascular disease in uremic patients显示文摘 | Liabeuf S Lenglet A Desjardins L | 2012 | Kidney Int2012，82，： | 1 |
| 4 | A Satellite Infrastructure for Health Early Warning in Post - disaster Health Management 显示文摘 | Chronaki CE Berthier A Lleo MM Esterle L Lenglet A Simon F Josseran L Lafaye M Matsakis Y Tabasco A Braak L | 2007 | Medinfo2007，12，1： | 1 |
| 5 | Surveillance status and recent data for Mycoplasma pneumoniae infections in the European Union and European Economic Area, January 2012显示文摘 | Lenglet A Herrador Z Magiorakos AP | 2012 | Eur Surveil2012，17，20： | 1 |
| 6 | Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La R6union 显示文摘 | G6rardin P Barau G Michault A Binmer M Randrianaivo H Choker G Lenglet Y Touret Y Bouveret A Grivard P Le Roux K Blanc S Schuffenecker I Couderc T Arenzana-Seisdedos F Lecuit M Robillard PY | 2008 | PLoS Med2008，5，3： | 1 |
| 7 | Surveillance status and recent data for Mycoplasma pneumoniae infections in the European Union and European Economic Area,January 2012显示文摘 | Lenglet A Herrador Z Magiorakos AP | 2012 | Euro Surveill2012，17，20： | 1 |
| 8 | Plasma beta-2microglobulin is associated with cardiovascular disease in uremic patients显示文摘 | Liabeuf S Lenglet A Desjardins L | 2012 | Kidney Int2012，82，12： | 1 |
| 9 | Molecular imaging of matrixmetalloproteinases in atherosclerotic plaques 显示文摘 | Lenglet S Thomas A Chaurand P | 2012 | Thromb Haemost2012，107，3： | 1 |
| 10 | A Riemannian approach to anisotropic filtering of tensor fields 显示文摘 | CASTANO M C A LENGLET C DERICHE R | 2007 | Signal Processing2007，87，2： | 1 |
| 11 | Use of nicotinamide to treat hyperphosphatemia in dialysis patients显示文摘 | Lenglet A Liabeuf S Guffroy P | 2013 | Drugs RD2013，13，3： | 1 |
| 12 | Comprehensive in vivo mapping of the human basal ganglia and thalamic connectome in individuals using 7T MRI显示文摘 | Lenglet C Abosch A Yacoub E | 2012 | PLo S One2012，7，29： | 1 |
| 13 | Molecular imaging of matrix metalloproteinases in atherosclerotic plaques显示文摘 | LENGLET S THOMAS A CHAURAND P | 2012 | Journal of Thrombosis and Haemostasis2012，107，3： | 1 |
| 14 | Molecular imaging of matrix metalloproteinases in atherosclerotic plaques显示文摘 | Lenglet S Thomas A Chaurand P | 2012 | Thromb Haemost2012，107，3： | 1 |
| 15 | Systemic and intra plaque mediators of inflammationare increased in patients symp tomatic for ischemic stroke显示文摘 | Montecucco F Lenglet S Gayet - Ageron A | 2010 | Stroke2010，41，： | 1 |
| 16 | Effectiveness and safety of apixaban and rivaroxaban vs warfarin in patients with atrial fibrillation and chronic kidney disease显示文摘BACKGROUND Randomized controlled trials(RCTs)of direct oral anticoagulants(DOACs)included a low proportion of atrial fibrillation(AF)patients with chronic kidney disease(CKD),and suggested that DOACs are safe and effective in patients with mild-to-moderate CKD.In a metanalysis of RCTs and observational studies,DOACs were associated with better efficacy(vs warfarin)in early CKD and had similar efficacy and safety profiles in patients with stages IV-V CKD.But few studies have provided data on the safety and effectiveness of each DOAC vs warfarin in patients with stage III CKD.The effectiveness and safety of DOACs in those patients are still subject to debate.AIM To assess and compare the effectiveness and safety of apixaban and rivaroxaban vs warfarin in this patient population.METHODS A cohort of patients with an inpatient or outpatient code for AF and stage III CKD who were newly prescribed apixaban and rivaroxaban was created using the administrative databases from the Quebec province of Canada between 2013 and 2017.The primary effectiveness outcome was a composite of ischemic stroke,systemic embolism,and death,whereas the primary safety outcome was a composite of major bleeding within a year of DOAC vs warfarin initiation.Treatment groups were compared in an under-treatment analysis using inverse probability of treatment weighting and Cox proportional hazards.RESULTS A total of 8899 included patients filled out a new oral anticoagulation therapy claim;3335 for warfarin and 5564 for DOACs.Compared with warfarin,15 mg and 20 mg rivaroxaban presented a similar effectiveness and safety composite risk.Apixaban 5.0 mg was associated with a lower effectiveness composite risk[Hazard ratio(HR)0.76;95%confidence interval(CI):0.65-0.88]and a similar safety risk(HR 0.94;95%CI:0.66-1.35).Apixaban 2.5 mg was associated with a similar effectiveness composite(HR 1.00;95%CI:0.79-1.26)and a lower safety risk(HR 0.65;95%CI:0.43-0.99.Although,apixaban 5.0 mg was associated with a better effectiveness(HR 0.76;95%CI:0.65-0.88),but a similar safety risk profile(HR 0.94;95%CI:0.66-1.35).The observed improvement in the effectiveness composite for apixaban 5.0 mg was driven by a reduction in mortality(HR 0.61;95%CI:0.43-0.88).CONCLUSION In comparison with warfarin,rivaroxaban and apixaban appear to be effective and safe in AF patients with stage III CKD. | Sylvie Perreault Laurie-Anne Boivin Proulx Aurélie Lenglet Ziad A Massy Marc Dorais | 2023 | World Journal of Nephrology2023，12，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员